Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
Anavex Life Sciences (Nasdaq: AVXL) will release fiscal 2026 first-quarter financial results on Monday, February 9, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Anavex Life Sciences (Nasdaq: AVXL) will release fiscal 2026 first-quarter financial results on Monday, February 9, 2026. Management will host a conference call and live webcast on that day at 8:30 am ET to review results and recent corporate developments.
Investors can join via Anavex’s website or by phone (U.S. dial-in 1 929 205 6099; Meeting ID 844 4149 6344; passcode 789539). A replay will be available on the company website for up to 30 days.
Details
News Market Reaction – AVXL
On Feb 3, the day this news came out, AVXL closed 2.88% below the previous close.
Data tracked by StockTitan Argus for the Feb 3 session.
Key Figures
- Earnings date
- February 9, 2026
- Fiscal 2026 Q1 results release
- Call time
- 8:30 am ET
- Conference call on February 9, 2026
- US dial-in
- 1 929 205 6099
- Conference call access number for U.S. participants
- Meeting ID
- 844 4149 6344
- Access ID for the February 9, 2026 conference call
- Passcode
- 789539
- Conference call passcode
- Replay duration
- 30 days
- Time replay will remain available on company website
Previous Earnings date Reports
-
Scheduled fiscal 2025 Q4 and year-end results with webcast and Q&A details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
central nervous system medical
cns medical
rett syndrome medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ET
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its first quarter of fiscal 2026 on Monday, February 9, 2026.
Management will host a conference call on Monday February 9, at 8:30 am ET to review financial results and discuss recent corporate developments. Following management’s remarks, there will be a question-and-answer session.
Webcast / Conference Call Information:
The live webcast of the conference call will be available on Anavex’s website at www.anavex.com.
The conference call can be also accessed by dialing 1 929 205 6099 for participants in the U.S. using the Meeting ID# 844 4149 6344 and reference passcode 789539. A replay of the conference call will be available on Anavex’s website for up to 30 days.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.